Patent · US Active

Antibodies that bind IL-4 and/or IL-13 and their uses

US11453727B2 · kind B2 · utility

2Cited by

78References

12Claims

0Family size

Assignee

Sanofi · FR

Inventors

Ercole Rao · Frankfurt am Main, DE
Vincent Mikol · Charenton-le-Pont, FR
Danxi Li · Skillman, US
Jochen Kruip · Frankfurt am Main, DE
Matthew Davison · Oklahoma City, US

Key dates

Filing date	Jul 28, 2020
Grant date	Sep 27, 2022
Priority date	—
Expiry date	Dec 2, 2040

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.